{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-043142","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2023-11-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.773293+00:00","generated_at":"2026-06-07T19:52:16.409838+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BriaCell reports new Phase 2 responder with 3-cycle orbital tumor resolution after 7 prior failed regimens","bullets":["Patient with proptosis from orbital metastatic breast cancer had remarkable improvement and pain reduction after 3 cycles of Bria-IMT combo.","Heavily pretreated patient had failed 7 prior regimens; continues treatment with well-tolerated regimen.","Second reported case of orbital tumor resolution; first patient had failed 12 regimens and 16 agents.","Additional Phase 2 survival updates and clinical data to be presented at San Antonio Breast Cancer Symposium Dec 6-7, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-043142","json":"https://secwatch.observer/filing/0001493152-23-043142.json","markdown":"https://secwatch.observer/filing/0001493152-23-043142.md","text":"https://secwatch.observer/filing/0001493152-23-043142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223043142/0001493152-23-043142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223043142/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T19:52:16.409838+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}